Preemptive Approach to Improving Survival in Epithelial Ovarian Cancer.

摘要

We have developed a mouse model of recurrent epithelial ovarian cancer for which we can monitor tumor formation, response and recurrence in vivo using live imaging. We are using this model to test UCN-01 and Olripraz in the consolidation setting. Despite demonstration of response of CAOV2-GFP/LUC cells in vivo to carboplatin, there remains variability between experiments, which we believe has to do with the age of the mice and/or their size when first injected with tumor cells, as well as the number of cells injected. We are also making progress toward developing the primary cells for use in xenograft formation that can be monitored through live imaging. To our knowledge, there are no reported animal models of recurrent ovarian cancer, yet recurrent disease is usually the lethal event for humans. Finding drugs that can target residual cells during remission is perhaps the best hope for delaying or preventing recurrence.